Last year, AstraZeneca PLC generated 8.40B USD for its biggest-performing segment, Farxiga. The United States made the largest contribution, accounting for 23.97B USD last year. For the latest quarter, AstraZeneca PLC reported the revenue of 61.02B USD for the period ending 2026-06-30, which came from the top-performing segment, Calquenc. United States contributed the highest revenue, at 6.68B USD.